Sara C Grijalba

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Prognostic Factors

Epstein Barr Virus

Patient Reported Outcomes

Top Venues

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Javier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco Javier Novo, Juan Garcia Valero, Patricia Pérez-Galán, Jose-Angel Martinez-Climent, Sergio Roa
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for immunotherapy of cancer 11 (2) (2023)
Javier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco Javier Novo, Juan Garcia Valero, Patricia Pérez-Galán, Jose-Angel Martinez-Climent, Sergio Roa
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for immunotherapy of cancer 11 (2) (2023)
Javier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco Javier Novo, Juan Garcia Valero, Patricia Pérez-Galán, Jose-Angel Martinez-Climent, Sergio Roa
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for immunotherapy of cancer 11 (2) (2023)
Javier Melchor, Marcos Garcia-Lacarte, Sara C Grijalba, Adrián Arnaiz-Leché, Marién Pascual, Carlos Panizo, Oscar Blanco, Victor Segura, Francisco Javier Novo, Juan Garcia Valero, Patricia Pérez-Galán, Jose-Angel Martinez-Climent, Sergio Roa
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma. Journal for immunotherapy of cancer 11 (2) (2023)